U.S. patent application number 11/972293 was filed with the patent office on 2008-07-17 for crystalline k-252b, sodium salt, methanolate pentahydrate.
This patent application is currently assigned to ABBOTT LABORATORIES. Invention is credited to Rodger F. Henry.
Application Number | 20080171868 11/972293 |
Document ID | / |
Family ID | 39618287 |
Filed Date | 2008-07-17 |
United States Patent
Application |
20080171868 |
Kind Code |
A1 |
Henry; Rodger F. |
July 17, 2008 |
CRYSTALLINE K-252b, SODIUM SALT, METHANOLATE PENTAHYDRATE
Abstract
A crystalline
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-k1]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one methanolate pentahydrate and ways
to make it are disclosed.
Inventors: |
Henry; Rodger F.; (Wildwood,
IL) |
Correspondence
Address: |
PAUL D. YASGER;ABBOTT LABORATORIES
100 ABBOTT PARK ROAD, DEPT. 377/AP6A
ABBOTT PARK
IL
60064-6008
US
|
Assignee: |
ABBOTT LABORATORIES
Abbott Park
IL
|
Family ID: |
39618287 |
Appl. No.: |
11/972293 |
Filed: |
January 10, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60885016 |
Jan 16, 2007 |
|
|
|
Current U.S.
Class: |
540/545 |
Current CPC
Class: |
C07D 498/22
20130101 |
Class at
Publication: |
540/545 |
International
Class: |
C07D 498/22 20060101
C07D498/22 |
Claims
1. Crystalline
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one methanolate pentahydrate
characterized in the monoclinic crystal system and P2.sub.1 space
group, when measured at about -100.degree. C. with Mo-K.alpha.
radiation, by lattice parameters a, b and c of 13.200
.ANG..+-.0.003 .ANG., 6.938 .ANG..+-.0.003 .ANG. and 15.617
.ANG..+-.0.007 .ANG., respectively, and .beta. of
104.674.degree..+-.0.007.
Description
[0001] This application claims priority to U.S. Provisional
application Ser. No. 60/885,016, filed Jan. 16, 2007.
FIELD OF THE INVENTION
[0002] This invention pertains to a crystalline sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one methanolate pentahydrate and ways
to make it.
BACKGROUND OF THE INVENTION
[0003] Because the relationship between different crystalline forms
of intermediates, and solvates thereof, in processes to make drugs
may provide guidance for further development, there is an existing
need in the chemical process and therapeutic arts for
identification of different crystalline forms of the intermediates,
or the solvates thereof, and ways to reproducibly make them.
SUMMARY OF THE INVENTION
[0004] One embodiment of this invention, therefore, pertains to
crystalline sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one methanolate pentahydrate
characterized in the monoclinic crystal system and P2.sub.1 space
group, when measured at about -100.degree. C. with Mo-K.alpha.
radiation, by lattice parameters a, b and c of 13.200
.ANG..+-.0.003 .ANG., 6.938 .ANG..+-.0.003 .ANG. and 15.617
.ANG..+-.0.007 .ANG., respectively, and .beta. of
104.674.degree.+0.007.
[0005] Still another embodiment pertains to a process for making
crystalline sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one comprising:
[0006] making and isolating or not isolating
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one;
[0007] providing a mixture comprising water, methanol and the
sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one, wherein the sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one is completely dissolved in the
water;
[0008] causing sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one methanolate pentahydrate to exist
in the mixture, wherein the sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one methanolate pentahydrate, when
isolated and measured in the monoclinic crystal system and P2.sub.1
space group at about -100.degree. C. with Mo-K.alpha. radiation, is
characterized by lattice parameters a, b and c of 13.200
.ANG..+-.0.003 .ANG., 6.938 .ANG..+-.0.003 .ANG. and 15.617
.ANG..+-.0.007 .ANG., respectively, and .beta. of
104.674.degree..+-.0.007; and
[0009] isolating the sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one methanolate pentahydrate.
[0010] Sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one methanolate pentahydrate prepared
as described in the preceding process.
DETAILED DESCRIPTION OF THE INVENTION
[0011] The synthesis of sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one is described in U.S. Pat. No.
4,923,986.
[0012] This invention pertains to discovery of sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',
1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one methanolate
pentahydrate, ways to make it having substantial crystalline,
chemical and diastereomeric purity, ways to characterize it,
compositions containing it and methods of treatment of diseases and
inhibition of adverse physiological events using it.
[0013] The term "amorphous," as used herein, means a supercooled
liquid or a viscous liquid which looks like a solid but does not
have a regularly repeating arrangement of molecules that is
maintained over a long range and does not have a melting point but
rather softens or flows above its glass transition temperature.
[0014] The term "anti-solvent," as used herein, means a solvent in
which a compound is substantially insoluble.
[0015] The term "sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one methanolate pentahydrate," as used
herein, means sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one with one methanol and five water
solvate molecules.
[0016] The term "crystalline," as used herein, means having a
regularly repeating arrangement of molecules or external face
planes.
[0017] The term "isolating" as used herein, means separating a
compound from a solvent, anti-solvent, or a mixture of solvent and
anti-solvent to provide a solid, semisolid or syrup. This is
typically accomplished by means such as centrifugation, filtration
with or without vacuum, filtration under positive pressure,
distillation, evaporation or a combination thereof. Isolating may
or may not be accompanied by purifying during which the chemical,
chiral or chemical and chiral purity of the isolate is increased.
Purifying is typically conducted by means such as crystallization,
distillation, extraction, filtration through acidic, basic or
neutral alumina, filtration through acidic, basic or neutral
charcoal, column chromatography on a column packed with a chiral
stationary phase, filtration through a porous paper, plastic or
glass barrier, column chromatography on silica gel, ion exchange
chromatography, recrystallization, normal-phase high performance
liquid chromatography, reverse-phase high performance liquid
chromatography, trituration and the like.
[0018] The term "miscible," as used herein, means capable of
combining without separation of phases.
[0019] The term "solvate," as used herein, means having on a
surface, in a lattice or on a surface and in a lattice, a solvent
such as water, acetic acid, acetone, acetonitrile, benzene,
chloroform, carbon tetrachloride, dichloromethane,
dimethylsulfoxide, 1,4-dioxane, ethanol, ethyl acetate, butanol,
tert-butanol, N,N-dimethylacetamide, N,N-dimethylformamide,
formamide, formic acid, heptane, hexane, isopropanol, methanol,
methyl ethyl ketone, 1-methyl-2-pyrrolidinone, mesitylene,
nitromethane, polyethylene glycol, propanol, 2-propanone, pyridine,
tetrahydrofuran, toluene, xylene, mixtures thereof and the like. A
specific example of a solvate is a hydrate, wherein the solvent on
the surface, in the lattice or on the surface and in the lattice,
is water. Hydrates may or may not have solvents other than water on
the surface, in the lattice or on the surface and in the lattice of
a substance.
[0020] The term "supersaturated," as used herein, means having a
compound in a solvent in which it is completely dissolved at a
certain temperature but at which the solubility of the compound in
the solvent at that certain temperature is exceeded.
[0021] Unless stated otherwise, percentages stated throughout this
specification are weight/weight (w/w) percentages.
[0022] Causing sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one methanolate pentahydrate to exist
in a mixture comprising sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-1,-
0-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrro-
lo[3,4-i][1,6]benzodiazocin-1-one, methanol and water, wherein the
sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one is completely dissolved in the
water and the methanol, is nucleation. In a preferred embodiment
for the practice of this invention, nucleation of sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one methanolate pentahydrate is made
to occur in methanol and water which is supersaturated with sodium
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one.
[0023] For the practice of this invention, nucleation may be made
to occur in a solution by techniques that are well-known to those
skilled in the art such as, for example, solvent removal,
temperature change, solvent-miscible anti-solvent addition,
solvent-immiscible anti-solvent addition, chafing or scratching the
interior of the container, preferably a glass container with a
glass rod or a glass bead or beads, or by a combination
thereof.
[0024] It is meant to be understood that, because many solvents and
anti-solvents contain impurities, the level of impurities in
solvents and anti-solvents for the practice of this invention, if
present, are at a low enough concentration that they do not
interfere with the intended use of the solvent in which they are
present.
EXAMPLE 1
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10--
(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo-
[3,4-i][1,6]benzodiazocin-1-one methanolate pentahydrate
[0025] A mixture of
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one and methanol and water in which
the
(9S-(9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-
-(carboxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrol-
o[3,4-i][1,6]benzodiazocin-1-one was partially soluble in the water
was warmed to 50.degree. C. until the
9.alpha.,10.beta.,12.alpha.))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(car-
boxylate)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-
-i][1,6]benzodiazocin-1-one completely dissolved, cooled to ambient
temperature and filtered.
[0026] The foregoing is meant to be illustrative of the invention
and not meant to limit it to disclosed embodiments. Variations and
changes obvious to one skilled in the art are intended to be within
the scope and nature of the invention as defined in the appended
claims.
* * * * *